Free Trial

Clearside Biomedical (CLSD) Stock Forecast & Price Target

Clearside Biomedical logo
$1.01
-0.01 (-0.98%)
(As of 11/1/2024 ET)

Clearside Biomedical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
6

Based on 6 Wall Street analysts who have issued ratings for Clearside Biomedical in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for CLSD.

Consensus Price Target

$5.17
411.55% Upside
According to the 6 analysts' twelve-month price targets for Clearside Biomedical, the average price target is $5.17. The highest price target for CLSD is $6.00, while the lowest price target for CLSD is $4.00. The average price target represents a forecasted upside of 411.55% from the current price of $1.01.
Get the Latest News and Ratings for CLSD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Clearside Biomedical and its competitors.

Sign Up

CLSD Analyst Ratings Over Time

TypeCurrent Forecast
11/3/23 to 11/2/24
1 Month Ago
10/4/23 to 10/3/24
3 Months Ago
8/5/23 to 8/4/24
1 Year Ago
11/3/22 to 11/3/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.17$4.83$4.60$5.60
Forecasted Upside411.55% Upside263.41% Upside314.41% Upside486.33% Upside
Consensus Rating
Buy
Buy
Buy
Buy

CLSD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CLSD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Clearside Biomedical Stock vs. The Competition

TypeClearside BiomedicalMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.79
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside411.55% Upside15,963.90% Upside10.55% Upside
News Sentiment Rating
Neutral News

See Recent CLSD News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/14/2024Chardan Capital
1 of 5 stars
D. Gataulin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00+424.01%
10/10/2024Needham & Company LLC
2 of 5 stars
 Boost TargetBuy ➝ Buy$4.00 ➝ $6.00+358.01%
8/27/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00+384.12%
6/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$5.00+362.96%
3/13/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$5.00+208.64%
3/13/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$5.00 ➝ $4.00+115.05%
4/28/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
11/9/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$8.00+459.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:22 AM ET.


CLSD Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Clearside Biomedical is $5.17, with a high forecast of $6.00 and a low forecast of $4.00.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares.

According to analysts, Clearside Biomedical's stock has a predicted upside of 411.55% based on their 12-month stock forecasts.

Clearside Biomedical has been rated by research analysts at Chardan Capital, HC Wainwright, and Needham & Company LLC in the past 90 days.

Analysts like Clearside Biomedical more than other "medical" companies. The consensus rating for Clearside Biomedical is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CLSD compares to other companies.


This page (NASDAQ:CLSD) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners